Belgium-based life sciences company Pronota has finally closed its second round of funding after nearly a year with a final total of €7.9m ($9.8m).
Johnson and Johnson Development Corporation, the in-house venture capital arm of the US-based consumer and medical goods company, and MP Healthcare Venture Management, a jointly-owned subsidiary of Mitsubishi Tanabe Pharma Corp and its parent Mitsubishi Chemical, had originally backed Pronota’s series B last summer.
The additional €1.5m ($1.9m) came from MedSciences Capital, the venture capital arm of…
